Pathologic assessment of vasculopathies in pulmonary hypertension

Giuseppe G. Pietra(National Heart Lung and Blood Institute), Rubin M. Tuder(University of Colorado Denver), Marc Humbert(Inserm), Ornella Leone(Policlinico S.Orsola-Malpighi), Susan Stewart(Stiftung Wissenschaft und Politik, German Institute for International and Security Affairs), Ivan M. Robbins(Vanderbilt University Medical Center), Frédérique Capron, Lynne Reid(Royal Brompton Hospital)
Journal of the American College of Cardiology
June 1, 2004
10.1016/j.jacc.2004.02.033
Cited by 713

Related Papers

2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
|European Heart Journal|2022|3.6k
Survival in Patients with Primary Pulmonary Hypertension
|Annals of Internal Medicine|1991|3.5k
Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE
|Allergy|2004|1.1k
The pulmonary endothelial glycocalyx regulates neutrophil adhesion and lung injury during experimental sepsis
|Nature Medicine|2012|834
Guidelines for autopsy investigation of sudden cardiac death: 2017 update from the Association for European Cardiovascular Pathology
|Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin|2017|538